Back to homepage

Tag "safety"

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going

Authors: Eleanor Liu, Nasar Aslam, Gaurav Nigam, Jimmy K Limdi

This narrative review summarizes the current literature regarding the mechanism of action of tofacitinib, data from registrational trials, emerging real-world evidence, and an overview of the most recent safety evidence. The authors explore evolving treatment paradigms and also present a brief overview of the next generation of JAK inhibitors in the pipeline.

More

Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions

Authors: Amalia Leceta, Aintzane García, Ander Sologuren, Cristina Campo

Keywords: allergic rhinoconjunctivitis, antihistamines, bilastine, drug information, drug interactions, medical information services, paediatrics, safety, urticaria. Citation: Leceta A, García A, Sologuren A, Campo C. Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment

More

Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review

Authors: Xenophon Kassianides BSc (Hons), MBBS, MRCP(UK), Sunil Bhandari MBChB, MRCP, FRCP, PhD, M Clin Edu, FHEA

This review focues on the links between iron and phosphate metabolism, the most recent comparative studies between third-generation i.v. iron compounds, the important role of fibroblast growth factor 23 (FGF23), and the impact of hypophosphataemia on the patient. This review also presents an algorithm that can be used in patients requiring i.v. iron in anticipation of potential hypophosphataemia.

More

Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review

Authors: Giulia Cassone MD, PhD, Marco Sebastiani MD, Caterina Vacchi MD, PhD, Gian Luca Erre MD, Carlo Salvarani MD, Andreina Manfredi MD, PhD

This review describes the available data and recent advances on the effectiveness and safety of MMF for the treatment of ILD related to RD, including rheumatoid arthritis, systemic sclerosis, primary Sjögren syndrome, systemic lupus erythematosus, idiopathic inflammatory myopathies, undifferentiated connective tissue disease, interstitial pneumonia with autoimmune features and antineutrophil cytoplasmic antibody-associated vasculitis.

More

Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease

Authors: Caterina Vacchi PhD, Andreina Manfredi MD, Giulia Cassone PhD, Gian Luca Erre MD, Carlo Salvarani MD, Marco Sebastiani MD

This article reviews the available efficacy and safety data on the use of rituximab in the treatment of rheumatic disease-related interstitial lung disease.

More